A5068815887- Nicotinic Acetylcholine Receptors Study
- Cholinesterase and Neurodegenerative Diseases
- Computational Drug Discovery Methods
- Stress Responses and Cortisol
- Neuroendocrine regulation and behavior
- Alzheimer's disease research and treatments
Culham Science Centre
2022-2023
Abstract Introduction The neuronal mechanism driving Alzheimer's disease (AD) is incompletely understood. Methods Immunohistochemistry, pharmacology, biochemistry, and behavioral testing are employed in two pathological contexts—AD a transgenic mouse model—to investigate T14, 14mer peptide, as key signaling molecule the neuropathology. Results T14 increases AD brains progresses conspicuous 5XFAD mice, where its immunoreactivity corresponds to that seen AD: neurons immunoreactive for...
A 14mer peptide, T14, is a possible signaling molecule driving neurodegeneration. Its levels are doubled in the Alzheimer brain, but its effects can be blocked at target alpha-7 receptor by cyclised variant, 'NBP14′, which has beneficial effects, transgenic mouse model, on behavioral and histochemical profile. Since antagonism of T14 evident therapeutic potential, we explore here an alternative method preventing action comparing efficacy NBP14 with proprietorial polyclonal antibody against...
T14, a 14mer peptide derived from the C-terminus of acetylcholinesterase (AChE) is signalling molecule that could drive neurodegeneration via alpha 7 nicotinic acetylcholine receptor. Its levels increase as Alzheimer's pathology progresses; however, cyclic variant compound, NBP14, can block effects endogenous linear counterpart in-vitro, ex vivo, and in vivo. Here, we explore antagonistic potential two 6mer peptides, NBP6A NBP6B. These are smaller versions designed to be more effective by...